Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Adagio Therapeutics $356 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Viveo R$1.9 billion IPO
We advised Viveo and the selling shareholders on its IPO and São Paulo Stock Exchange listing
LivaNova $345 million equity offering
We advised the underwriters on the SEC-registered offering
New Frontier Health going-private transaction
We are advising the special committee of the board of New Frontier Health in connection with its going-private acquisition
Nurix Therapeutics $150 million at-the-market offering
We advised the sales agent on the stock offering
RxSight $117.6 million IPO
We advised the underwriters in connection with the IPO and Nasdaq listing
Tenaya Therapeutics $207 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Colfax $287.3 million secondary offering
We advised certain selling stockholders on the transaction
SOPHiA GENETICS $234 million IPO and $20 million private placement
We advised SOPHiA GENETICS on its IPO, Nasdaq listing and concurrent private placement
Royalty Pharma $1.3 billion senior notes offering
We advised Royalty Pharma on its SEC-registered investment-grade notes offering, including $600 million in social bonds